Celgene to buy Juno Therapeutics

Celgene Corp. (Nasdaq: CELG) agreed to acquire Juno Therapeutics Inc. (Nasdaq: JUNO) for a premium of approximately $9 billion in cash. Shares of Celgene added 26 cents to close at $102.91 while Juno stock surged $18.19 to close at $86.00.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.